


Behçet's Disease: Drug pathway

Less complex disease

Severe disease



Initial therapy - less complex disease

Oral colchicine 500mcg bd
Topical steroid (mouthwash, gel, spray)
Topical non-steroidal (anti-inflammatory mouthwash)
Triple mouthwash
Antibiotics

70% Effective Ineffective 30%

Step up therapy

Azathioprine 2mg/kg (up to dose 200mg/day) usually started at low dose before increasing
 OR
Mycophenolate (up to 3g/day)
 OR
Tacrolimus up to 4mg bd (dosed on plasma trough concentration)
 OR
Steroid – variable daily, weekly or monthly
 Oral variable dose
 Intramuscular
 Intravenous

66% Effective Ineffective 33%

TNF inhibitor

Infliximab 5mg/kg for 4 doses then consider swapping to subcutaneous TNFi after 4 doses.
 Stop therapy after 6 months. Restart if flare (70% flare within 3 months)

Treatment

Initial Therapy
 Topical Steroid; Intraocular; Intravenous; Oral
Maintenance Therapy
 oral steroid
 Azathioprine 2mg/kg/day / Mycophenolate (up to 3g/day)
 Cyclosporin 2.5-5mg/kg/day

80% Effective Ineffective 20%

Flare in 50%

Step-up treatment

Infliximab 5mg/kg for 4 doses at a dosing frequency of every 6 weeks, then consider swapping to subcutaneous TNFi after 4 doses.
 Stop therapy after 12 months. Restart if flare (70% flare within 3 months)
 OR
Interferon Alpha
 Average dose 30mcg once a week for 6 months (restart if flare)

90% Effective Ineffective 10%

Second line step-up treatment

Alemtuzumab (temporarily unavailable)
 OR
Rituximab one cycle of 2 infusions @1,000mg/infusion

Treatment

Initial therapy
 Intravenous steroid
 Azathioprine 2mg/kg per day

50% Effective Ineffective 50%

Step-up treatment

Infliximab 5mg/kg for 4 doses then swap to either adalimumab 40mg eow or etanercept 50mg once a wk. Stop therapy after 6 months. Restart if flare (70% flare within 3 mnths)
 OR
Interferon Alpha average dose 30mcg once a week for 6 months (restart if flare)
 OR
Cyclophosphamide (1.0 -> 1.5mg/kg daily IV at increasing intervals 0, 2, 4, 8, 12, weeks)

90% Effective Ineffective 10%

Second line step-up treatment

Alemtuzumab (temporarily unavailable)
 OR
Rituximab one cycle of 2 infusions @1,000mg/infusion

Drugs

The bottom line: mucocutaneous disease -
 75% patients taking baseline drugs
 20% patients on step up therapy
 5% patients requiring TNFi

The bottom line: eye disease -
 85% patients taking baseline drugs
 10% patients requiring TNFi
 5% patients requiring IFN/rituximab

The bottom line: other major organ flare -
 60% patients taking steroid/azathioprine
 30% patients on cyclophosphamide
 10% patients requiring a biologic agent